Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IGC 
India Globalization Capital Inc (IGC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: IGC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -18.71% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 22.76M USD | Price to earnings Ratio - | 1Y Target Price 3.88 |
Price to earnings Ratio - | 1Y Target Price 3.88 | ||
Volume (30-day avg) 368751 | Beta 1.21 | 52 Weeks Range 0.26 - 0.91 | Updated Date 04/1/2025 |
52 Weeks Range 0.26 - 0.91 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -730.74% |
Management Effectiveness
Return on Assets (TTM) -54.7% | Return on Equity (TTM) -115.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 22510272 | Price to Sales(TTM) 18.41 |
Enterprise Value 22510272 | Price to Sales(TTM) 18.41 | ||
Enterprise Value to Revenue 18.21 | Enterprise Value to EBITDA -2.54 | Shares Outstanding 79685200 | Shares Floating 72280819 |
Shares Outstanding 79685200 | Shares Floating 72280819 | ||
Percent Insiders 7.52 | Percent Institutions 20.91 |
Analyst Ratings
Rating 5 | Target Price 3.75 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
India Globalization Capital Inc
Company Overview
History and Background
India Globalization Capital, Inc. (IGC) was founded in 2005. Initially focused on infrastructure projects in India, it has evolved to concentrate on the life sciences sector, particularly cannabinoid-based therapies.
Core Business Areas
- Life Sciences: IGC focuses on the development of cannabinoid-based therapies for conditions such as Alzheimer's disease, pain management, and other medical conditions. It conducts research, clinical trials, and seeks regulatory approvals for its products.
Leadership and Structure
Ram Mukunda serves as the CEO. The company has a board of directors and a management team overseeing its research, development, and commercialization efforts.
Top Products and Market Share
Key Offerings
- IGC-AD1: IGC-AD1 is a cannabinoid-based formulation being developed as a potential treatment for Alzheimer's disease. It's currently in clinical trials. Market share is negligible at this stage, awaiting successful trial outcomes and FDA approval. Competitors include pharmaceutical companies like Biogen, Eli Lilly, and Eisai who are developing more traditional Alzheimer's drugs.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the cannabinoid therapeutics sector, is experiencing growth driven by increased research, changing regulations, and patient demand. The Alzheimer's disease treatment market is substantial, with a significant unmet need.
Positioning
IGC is a small player in the pharmaceutical industry focusing on niche cannabinoid-based therapies. Its competitive advantage lies in its proprietary formulations and research efforts within this specific area. However, it faces stiff competition from established pharmaceutical companies with greater resources.
Total Addressable Market (TAM)
The Alzheimer's disease market is expected to reach hundreds of billions of dollars annually. IGC aims to capture a portion of this TAM with its IGC-AD1 if successful in clinical trials and regulatory approvals. Their current position represents a very small fraction of the total market due to their developmental stage.
Upturn SWOT Analysis
Strengths
- Proprietary cannabinoid-based formulations
- Focus on underserved medical needs
- Experienced management team in the life sciences sector
Weaknesses
- Limited financial resources compared to competitors
- Dependence on successful clinical trial outcomes
- Regulatory hurdles in the pharmaceutical industry
- Small market capitalization and thinly traded stock.
Opportunities
- Potential for breakthrough Alzheimer's treatment
- Partnerships with larger pharmaceutical companies
- Expansion into other cannabinoid-based therapies
- Positive changes in cannabis regulations
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Unfavorable regulatory changes
- Difficulty in raising capital
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- ESAI
Competitive Landscape
IGC faces a highly competitive landscape dominated by large pharmaceutical companies. It must demonstrate significant clinical success to establish a viable market presence.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: IGC's growth has been limited due to its early stage development and dependence on research and development outcomes.
Future Projections: Future growth projections are highly speculative and dependent on successful clinical trials, regulatory approvals, and commercialization of its products. Analyst estimates vary significantly due to the inherent uncertainty.
Recent Initiatives: Recent initiatives include advancing clinical trials for IGC-AD1 and seeking funding to support these efforts.
Summary
IGC is a high-risk, high-reward pharmaceutical company focused on cannabinoid-based therapies. Its future is heavily reliant on the success of IGC-AD1's clinical trials. The company's limited financial resources and strong competition pose significant challenges, while positive clinical results and strategic partnerships could fuel significant growth.
Similar Companies
- BIIB
- GWPH
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is based on available public information and is not financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share data is based on current available information and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About India Globalization Capital Inc
Exchange NYSE MKT | Headquaters Potomac, MD, United States | ||
IPO Launch date 2006-04-13 | President, CEO & Director Mr. Ram Mukunda | ||
Sector Healthcare | Industry Biotechnology | Full time employees 67 | Website https://igcpharma.com |
Full time employees 67 | Website https://igcpharma.com | ||
IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.